|
Board of ERIS Lifesciences recommends interim dividend> |
|
Eris Lifesciences spurts after Q4 PAT skyrockets 200% YoY to Rs 282 cr> |
|
ERIS Lifesciences to hold board meeting> |
|
ERIS Lifesciences allots 24,396 equity shares under ESOP> |
|
Eris Lifesciences receives affirmation in credit ratings> |
|
Ola Electric Mobility Ltd leads losers in 'A' group> |
|
Eris Lifesciences drops after HALMED flags non-compliance issues at subsidiary units> |
|
Eris Lifesciences gains after partnering with Natco Pharma for launching Semaglutide in India> |
|
ERIS Lifesciences consolidated net profit rises 19.05% in the December 2025 quarter> |
|
ERIS Lifesciences schedules board meeting> |